112 related articles for article (PubMed ID: 2597445)
1. A comparison of the antiplatelet effect of aspirin on human and bovine platelets.
Swier P; Mohammad SF; Olsen DB; Kolff WJ
ASAIO Trans; 1989; 35(3):205-8. PubMed ID: 2597445
[TBL] [Abstract][Full Text] [Related]
2. Interaction of antiplatelet drugs in vitro: aspirin, iloprost, and the nitric oxide donors SIN-1 and sodium nitroprusside.
Negrescu EV; Grünberg B; Kratzer MA; Lorenz R; Siess W
Cardiovasc Drugs Ther; 1995 Aug; 9(4):619-29. PubMed ID: 8547213
[TBL] [Abstract][Full Text] [Related]
3. Abciximab treatment in vitro after aspirin treatment in vivo has additive effects on platelet aggregation, ATP release, and P-selectin expression.
Scazziota A; Altman R; Rouvier J; Gonzalez C; Ahmed Z; Jeske WP; Walenga JM; Fareed J
Thromb Res; 2000 Dec; 100(6):479-88. PubMed ID: 11152927
[TBL] [Abstract][Full Text] [Related]
4. The antiplatelet activity of camel urine.
Alhaidar A; Abdel Gader AG; Mousa SA
J Altern Complement Med; 2011 Sep; 17(9):803-8. PubMed ID: 21854200
[TBL] [Abstract][Full Text] [Related]
5. The potent inhibition of vapiprost, a novel thromboxane A2 receptor antagonist, on the secondary aggregation and ATP release of human platelets.
Horie S; Yamada M; Satoh M; Noritake S; Hiraishi S; Kizaki K; Kurusu O; Nakahara T; Ishii H; Kazama M
Biol Pharm Bull; 1997 Jun; 20(6):625-31. PubMed ID: 9212979
[TBL] [Abstract][Full Text] [Related]
6. Short-term exposure of platelets to glucose impairs inhibition of platelet aggregation by cyclooxygenase inhibitors.
Kobzar G; Mardla V; Samel N
Platelets; 2011; 22(5):338-44. PubMed ID: 21557683
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms of aggregation inhibition by aspirin and nitrate-aspirin prodrugs in human platelets.
Harmon S; Inkielewicz-Stepniak I; Jones M; Ledwidge M; Santos-Martinez MJ; Medina C; Radomski MW; Gilmer JF
J Pharm Pharmacol; 2012 Jan; 64(1):77-89. PubMed ID: 22150675
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of platelet aggregation and thromboxane production by low concentrations of aspirin in vitro.
Sils D; Rodgers SE; Lloyd JV; Wilson KM; Siebert DM; Bochner F
Clin Sci (Lond); 1988 May; 74(5):491-7. PubMed ID: 3370916
[TBL] [Abstract][Full Text] [Related]
9. Characterization of platelet aggregation responses in microminipigs: Comparison with miniature pigs and the influence of dual antiplatelet administration of aspirin plus prasugrel.
Ohno K; Tomizawa A; Jakubowski JA; Mizuno M; Sugidachi A
Thromb Res; 2015 May; 135(5):933-8. PubMed ID: 25776467
[TBL] [Abstract][Full Text] [Related]
10. Response to aspirin and clopidogrel monitored with different platelet function methods.
Mani H; Linnemann B; Luxembourg B; Kirchmayr K; Lindhoff-Last E
Platelets; 2006 Aug; 17(5):303-10. PubMed ID: 16928602
[TBL] [Abstract][Full Text] [Related]
11. Failure of aspirin to impair bovine platelet function.
Gentry PA; Tremblay RR; Ross ML
Am J Vet Res; 1989 Jun; 50(6):919-22. PubMed ID: 2764343
[TBL] [Abstract][Full Text] [Related]
12. Role of platelets in aspirin-sensitive bronchoconstriction in the guinea-pig; interactions with salicylic acid.
Lefort J; Vargaftig BB
Br J Pharmacol; 1978 May; 63(1):35-42. PubMed ID: 647162
[TBL] [Abstract][Full Text] [Related]
13. Triggering by Paf-acether and adrenaline of cyclo-oxygenase-independent platelet aggregation.
Fouque F; Vargaftig BB
Br J Pharmacol; 1984 Nov; 83(3):625-33. PubMed ID: 6439269
[TBL] [Abstract][Full Text] [Related]
14. Increased platelet sensitivity among individuals with aspirin resistance - platelet aggregation to submaximal concentration of arachidonic acid predicts response to antiplatelet therapy.
Guthikonda S; Mangalpally K; Vaduganathan M; Patel R; Delao T; Bergeron AL; Dong JF; Lev EI; Kleiman NS
Thromb Haemost; 2008 Jul; 100(1):83-9. PubMed ID: 18612542
[TBL] [Abstract][Full Text] [Related]
15. Assessment of the antiplatelet effects of low to medium dose aspirin in the early and late phases after ischaemic stroke and TIA.
McCabe DJ; Harrison P; Mackie IJ; Sidhu PS; Lawrie AS; Purdy G; Machin SJ; Brown MM
Platelets; 2005 Aug; 16(5):269-80. PubMed ID: 16011977
[TBL] [Abstract][Full Text] [Related]
16. Human platelet alphaIIbeta3 integrin binding affinity and specificity of SJ874: antiplatelet efficacy versus aspirin.
Mousa SA; Forsythe M; Bozarth J; Jin F; Confalone PN
Coron Artery Dis; 2000 Oct; 11(7):563-70. PubMed ID: 11023245
[TBL] [Abstract][Full Text] [Related]
17. Influence of aspirin and carbacyclin on bovine platelet function.
Rao GH; Ericson DG; Weiss DJ; Parks PG; White JG
ASAIO J; 1992; 38(4):830-4. PubMed ID: 1450481
[TBL] [Abstract][Full Text] [Related]
18. In-vitro and ex-vivo inhibition of blood platelet aggregation by naftazone.
Durand P; Bloy C; Peltier-Pujol F; Blache D
J Pharm Pharmacol; 1996 Jun; 48(6):566-72. PubMed ID: 8832488
[TBL] [Abstract][Full Text] [Related]
19. Dose- and time-dependent antiplatelet effects of aspirin.
Perneby C; Wallén NH; Rooney C; Fitzgerald D; Hjemdahl P
Thromb Haemost; 2006 Apr; 95(4):652-8. PubMed ID: 16601836
[TBL] [Abstract][Full Text] [Related]
20. Does pycnogenol intensify the efficacy of acetylsalicylic acid in the inhibition of platelet function? In vitro experience.
Golański J; Muchova J; Golański R; Durackova Z; Markuszewski L; Watała C
Postepy Hig Med Dosw (Online); 2006; 60():316-21. PubMed ID: 16819430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
